Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2002 1
2004 2
2005 3
2006 2
2008 2
2009 5
2010 6
2011 1
2012 4
2013 5
2014 5
2015 4
2016 4
2017 1
2018 9
2019 3
2020 6
2021 10
2022 10
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Levis MJ, Perl AE, Schiller GJ, Fathi AT, Roboz GJ, Wang ES, Altman JK, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith CC. Levis MJ, et al. Among authors: schiller gj. Blood Adv. 2024 Mar 19:bloodadvances.2023010619. doi: 10.1182/bloodadvances.2023010619. Online ahead of print. Blood Adv. 2024. PMID: 38502195
Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components.
Wheeler AP, Snyder EL, Refaai MA, Cohn CS, Poisson J, Fontaine MJ, Sehl M, Nooka AK, Uhl L, Spinella PC, Fenelus M, Liles DK, Coyle T, Becker J, Jeng MR, Gehrie EA, Spencer BR, Young PP, Johnson AD, O'Brien J, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla S, Liu K, Bentow S, Varrone J, Benjamin RJ, Corash L. Wheeler AP, et al. Among authors: schiller gj. Blood Adv. 2024 Mar 6:bloodadvances.2023012425. doi: 10.1182/bloodadvances.2023012425. Online ahead of print. Blood Adv. 2024. PMID: 38447116
Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis.
Sasine JP, Kozlova NY, Valicente L, Dukov J, Tran DH, Himburg HA, Kumar S, Khorsandi S, Chan A, Grohe S, Li M, Kan J, Sehl ME, Schiller GJ, Reinhardt B, Singh BK, Ho R, Yue P, Pasquale EB, Chute JP. Sasine JP, et al. Among authors: schiller gj. Cancer Res. 2024 Mar 15;84(6):919-934. doi: 10.1158/0008-5472.CAN-23-1950. Cancer Res. 2024. PMID: 38231476 Free PMC article.
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. Cai SF, et al. Among authors: schiller gj. Blood Adv. 2024 Jan 23;8(2):429-440. doi: 10.1182/bloodadvances.2023010563. Blood Adv. 2024. PMID: 37871309 Free PMC article.
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff PJ, Jeyakumar D, Mao D, Adhikary S, Zhou L, Schuberth PC, Damico Khalid R, Ghobadia A. Shah BD, et al. Among authors: schiller gj. J Immunother Cancer. 2023 Aug;11(8):e007118. doi: 10.1136/jitc-2023-007118. J Immunother Cancer. 2023. PMID: 37648261 Free PMC article.
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
Schiller GJ, Lipe BC, Bahlis NJ, Tuchman SA, Bensinger WI, Sutherland HJ, Lentzsch S, Baljevic M, White D, Kotb R, Chen CI, Rossi A, Biran N, LeBlanc R, Grosicki S, Martelli M, Gunsilius E, Špička I, Stevens DA, Facon T, Mesa MG, Zhang C, Van Domelen DR, Bentur OS, Gasparetto C. Schiller GJ, et al. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e286-e296.e4. doi: 10.1016/j.clml.2023.06.001. Epub 2023 Jun 5. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37393120 Free article.
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ. Pratz KW, et al. Among authors: schiller gj. J Clin Oncol. 2023 Sep 10;41(26):4236-4246. doi: 10.1200/JCO.22.02721. Epub 2023 Jun 28. J Clin Oncol. 2023. PMID: 37379495 Clinical Trial.
Fosmanogepix Therapy of Disseminated Fusarium Infection.
Winston DJ, Young PA, Schlamm HT, Schiller GJ. Winston DJ, et al. Among authors: schiller gj. Clin Infect Dis. 2023 Sep 18;77(6):848-850. doi: 10.1093/cid/ciad309. Clin Infect Dis. 2023. PMID: 37220752
85 results